Health-care companies rose amid optimism about earnings growth in the sector. Shares of Danish obesity drug maker Novo Nordisk rose by 5.8%, recouping some recent losses. Rival Eli Lilly rose modestly ...

Shares of Azenta rose on Wednesday after the company's board of directors approved the repurchase of up to $250 million of common stock. Shares rose 5% to $37.23, though are down 20% year-to-date. The ...

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market ...

Azenta, Inc. (Nasdaq: AZTA) today announced that its Board of Directors has approved a share repurchase program under which ...

· Biologica, a women’s health company, has launched with a suite of stage-specific daily essentials packed in recyclable tins.

Azacitidine plus venetoclax significantly improved multiple outcomes for certain patients with acute myeloid leukemia ...

A major earnings reset and fresh fund interest could mark a turning point for this formerly high-flying life-sciences stock.

Azenta shows strong organic growth, margin expansion, $1B+ asset value, rebounding sales multiples, and positive FY26 guidance. See why AZTA stock is a hold.

From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.

The investment firm expressed optimism about Azenta’s trajectory, noting that an upcoming investor day in a few weeks should provide significant insight into management’s longer-term view. Raymond ...

What Happened? Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 4.2% in the afternoon session after a report revealed that the White House plans to pitch a two-year extension of Obamacare ...